These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27722869)

  • 1. Plague Vaccines: Status and Future.
    Sun W
    Adv Exp Med Biol; 2016; 918():313-360. PubMed ID: 27722869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing live vaccines against plague.
    Sun W; Roland KL; Curtiss R
    J Infect Dev Ctries; 2011 Sep; 5(9):614-27. PubMed ID: 21918302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational considerations about development of live attenuated Yersinia pestis vaccines.
    Sun W; Curtiss R
    Curr Pharm Biotechnol; 2013; 14(10):878-86. PubMed ID: 24372254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live-attenuated Yersinia pestis vaccines.
    Wang X; Zhang X; Zhou D; Yang R
    Expert Rev Vaccines; 2013 Jun; 12(6):677-86. PubMed ID: 23750796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
    Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
    mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against bubonic and pneumonic plague.
    Titball RW; Williamson ED
    Vaccine; 2001 Jul; 19(30):4175-84. PubMed ID: 11457543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral vaccination against plague using Yersinia pseudotuberculosis.
    Demeure CE; Derbise A; Carniel E
    Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
    Quenee LE; Schneewind O
    Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary hemochromatosis restores the virulence of plague vaccine strains.
    Quenee LE; Hermanas TM; Ciletti N; Louvel H; Miller NC; Elli D; Blaylock B; Mitchell A; Schroeder J; Krausz T; Kanabrocki J; Schneewind O
    J Infect Dis; 2012 Oct; 206(7):1050-8. PubMed ID: 22896664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
    Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for new plague vaccines.
    Feodorova VA; Corbel MJ
    Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.
    Oyston PC; Mellado-Sanchez G; Pasetti MF; Nataro JP; Titball RW; Atkins HS
    Microb Pathog; 2010 May; 48(5):191-5. PubMed ID: 20096773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
    D'Arco C; McCormick AA; Arnaboldi PM
    Vaccine; 2021 Mar; 39(9):1435-1444. PubMed ID: 33531196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency of killed plague vaccines prepared from avirulent Yersinia pestis.
    Williams JE; Altieri PL; Berman S; Lowenthal JP; Cavanaugh DC
    Bull World Health Organ; 1980; 58(5):753-6. PubMed ID: 6975184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.
    Lin JS; Szaba FM; Kummer LW; Chromy BA; Smiley ST
    J Immunol; 2011 Jul; 187(2):897-904. PubMed ID: 21653834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
    Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmonella-based plague vaccines for bioterrorism.
    Calhoun LN; Kwon YM
    J Microbiol Immunol Infect; 2006 Apr; 39(2):92-7. PubMed ID: 16604240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Protection Against
    Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
    Front Immunol; 2022; 13():793382. PubMed ID: 35154110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.